Literature DB >> 23027318

Two novel equations to estimate kidney function in persons aged 70 years or older.

Elke S Schaeffner1, Natalie Ebert, Pierre Delanaye, Ulrich Frei, Jens Gaedeke, Olga Jakob, Martin K Kuhlmann, Mirjam Schuchardt, Markus Tölle, Reinhard Ziebig, Markus van der Giet, Peter Martus.   

Abstract

BACKGROUND: In older adults, current equations to estimate glomerular filtration rate (GFR) are not validated and may misclassify elderly persons in terms of their stage of chronic kidney disease.
OBJECTIVE: To derive the Berlin Initiative Study (BIS) equation, a novel estimator of GFR in elderly participants.
DESIGN: Cross-sectional. Data were split for analysis into 2 sets for equation development and internal validation.
SETTING: Random community-based population of a large insurance company. PARTICIPANTS: 610 participants aged 70 years or older (mean age, 78.5 years). INTERVENTION: Iohexol plasma clearance measurement as gold standard. MEASUREMENTS: GFR, measured as the plasma clearance of the endogenous marker iohexol, to compare performance of existing equations of estimated GFR with measured GFR of the gold standard; estimation of measured GFR from standardized creatinine and cystatin C levels, sex, and age in the learning sample; and comparison of the BIS equations (BIS1: creatinine-based; BIS2: creatinine- and cystatin C-based) with other estimating equations and determination of bias, precision, and accuracy in the validation sample.
RESULTS: The new BIS2 equation yielded the smallest bias followed by the creatinine-based BIS1 and Cockcroft-Gault equations. All other equations considerably overestimated GFR. The BIS equations confirmed a high prevalence of persons older than 70 years with a GFR less than 60 mL/min per 1.73 m2 (BIS1, 50.4%; BIS2, 47.4%; measured GFR, 47.9%). The total misclassification rate for this criterion was smallest for the BIS2 equation (11.6%), followed by the cystatin C equation 2 (15.1%) proposed by the Chronic Kidney Disease Epidemiology Collaboration. Among the creatinine-based equations, BIS1 had the smallest misclassification rate (17.2%), followed by the Chronic Kidney Disease Epidemiology Collaboration equation (20.4%). LIMITATION: There was no validation by an external data set.
CONCLUSION: The BIS2 equation should be used to estimate GFR in persons aged 70 years or older with normal or mild to moderately reduced kidney function. If cystatin C is not available, the BIS1 equation is an acceptable alternative. PRIMARY FUNDING SOURCE: Kuratorium für Dialyse und Nierentransplatation (KfH) Foundation of Preventive Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027318     DOI: 10.7326/0003-4819-157-7-201210020-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  186 in total

Review 1.  Acute Renal Failure of Nosocomial Origin.

Authors:  Mark Dominik Alscher; Christiane Erley; Martin K Kuhlmann
Journal:  Dtsch Arztebl Int       Date:  2019-03-01       Impact factor: 5.594

2.  Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C.

Authors:  Hans Pottel; Pierre Delanaye; Elke Schaeffner; Laurence Dubourg; Bjørn Odvar Eriksen; Toralf Melsom; Edmund J Lamb; Andrew D Rule; Stephen T Turner; Richard J Glassock; Vandréa De Souza; Luciano Selistre; Karolien Goffin; Steven Pauwels; Christophe Mariat; Martin Flamant; Natalie Ebert
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

3.  Chronic kidney disease and the risk of incident hearing loss.

Authors:  Shruti Gupta; Sharon G Curhan; Karen J Cruickshanks; Barbara E K Klein; Ronald Klein; Gary C Curhan
Journal:  Laryngoscope       Date:  2019-05-28       Impact factor: 3.325

4.  Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function : Post hoc analysis of a prospective cohort.

Authors:  Vincenzo Livio Malavasi; Daniele Pettorelli; Elisa Fantecchi; Cristina Zoccali; Giuliana Laronga; Tommaso Trenti; Gregory Yoke Hong Lip; Giuseppe Boriani
Journal:  Intern Emerg Med       Date:  2018-05-07       Impact factor: 3.397

5.  Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine- vs. Cystatin C-Based Formulae.

Authors:  Anne Jacobs; Carolien Benraad; Jack Wetzels; Marcel Olde Rikkert; Cornelis Kramers
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

Review 6.  Biomarkers in chronic kidney disease, from kidney function to kidney damage.

Authors:  Salvador Lopez-Giacoman; Magdalena Madero
Journal:  World J Nephrol       Date:  2015-02-06

7.  Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS.

Authors:  Tiffany A Freed; Josef Coresh; Lesley A Inker; Douglas R Toal; Regis Perichon; Jingsha Chen; Kelli D Goodman; Qibo Zhang; Jessie K Conner; Deirdre M Hauser; Kate E T Vroom; Maria L Oyaski; Jacob E Wulff; Gudný Eiríksdóttir; Vilmundur Gudnason; Vicente E Torres; Lisa A Ford; Andrew S Levey
Journal:  Clin Chem       Date:  2019-01-15       Impact factor: 8.327

8.  Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?

Authors:  Youssef Bennis; Amandine Savry; Magali Rocca; Laurence Gauthier-Villano; Pascale Pisano; Bertrand Pourroy
Journal:  Int J Clin Pharm       Date:  2014-01-17

Review 9.  Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.

Authors:  Mauro Molteni; Mario Bo; Giovanni Di Minno; Giuseppe Di Pasquale; Simonetta Genovesi; Danilo Toni; Paolo Verdecchia
Journal:  Intern Emerg Med       Date:  2017-04-24       Impact factor: 3.397

10.  A comparison between 2017 FAS and 2012 CKD-EPI equations: a multi-center validation study in Chinese adult population.

Authors:  Zhenzhu Yong; Fen Li; Xiaohua Pei; Xun Liu; Dan Song; Xiaoxuan Zhang; Weihong Zhao
Journal:  Int Urol Nephrol       Date:  2018-10-24       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.